Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Post by dt_coreon Nov 15, 2012 12:48pm
502 Views
Post# 20605249

SOME QUICK HEM NUMBERS

SOME QUICK HEM NUMBERS

 

 

 

HEMISPHERE GPS CORE SEGMENT PROFORMA FORECAST      
  AG. CORE SEGMENT LTM 1- TIME ITEMS AG JUNCTION GROWTH CLAAS DEAL ORGANIC GROWTH 2013E
SALES 54,475,000   3,500,000 10,000,000 4,000,000 71,975,000
TOTAL COSTS -57,946,696 588,870 -1,820,000 -5,200,000 -2,080,000 -66,457,826
SAVINGS 7,000,000         7,000,000
PROFIT 3,528,304 588,870 1,680,000 4,800,000 1,920,000 12,517,174
EPS FD 0.05         0.17
             
TARGET PRICE:            
P/E of 15x           2.54
P/E of 20x           3.38

I'm doing this real quick, so call this my rough guess as to what 2013 proforma could look like (in other words, what the businesses ongoing normalized operations would look like... the number investors will focus on). I would call this a conservative forecast given I'm only applying 48% GM for agjunction, claas, and organic growth (e.g. MAX, new products, Stara sales increase etc).

Would be interested in hearing the opinions/views of others. Obviously there is lots of execution risk but if the company can deliver I still see a lot of upside to the share price.

Bullboard Posts